Philip J. Gold

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

Heinz‐Josef Lenz, Eric Van Cutsem, Shirin Khambata‐Ford et al. · Journal of Clinical Oncology · 2006 · 536 citations · Full text

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 415 citations · Full text

Surgical Oncology, Hepatology, Medicine +8

UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan

Leslie E. Carlini, Neal J. Meropol, John L. Bever et al. · Clinical Cancer Research · 2005 · 261 citations · Full text

Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer.

Paul B. Chapman, Tina Lester, E. S. Casper et al. · Journal of Clinical Oncology · 1987 · 219 citations

Immunology, Cell Death, Pharmacotherapy +19

First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma

Andrew X. Zhu, Philip J. Gold, Anthony B. El-Khoueiry et al. · Clinical Cancer Research · 2013 · 192 citations · Full text